Tivdak Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The tivdak market research report is one of a series of new reports that provides tivdak market statistics, including tivdak industry global market size, regional shares, competitors with a tivdak market share, detailed tivdak market segments, market trends and opportunities, and any further data you may need to thrive in the tivdak industry. This Tivdak market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to growing government initiatives to spread disease awareness, rising incidence of HPV infections, increasing demand for targeted therapy, increasing educational programs, and rising incidence of cervical cancer. Major trends in the forecast period include the development of targeted therapies, advances in diagnostic tools and preventive measures, the introduction of immunotherapies, the use of bevacizumab in advanced cervical cancer, and the approval of Avastin for cervical cancer treatment.

The rising incidence of cervical cancer is expected to drive the growth of the Tivdak market. Cervical cancer, which originates in the cervix - the lower part of the uterus - has been increasing primarily due to persistent HPV infections and insufficient screening, particularly in areas with limited access to healthcare. Tivdak (tisotumab vedotin) is used to treat recurrent or metastatic cervical cancer by targeting Trop-2 on cancer cells and delivering chemotherapy directly to the tumor. For example, in May 2024, the Canadian Cancer Society projected that 1,600 women in Canada would be diagnosed with cervical cancer, and 400 would die from it. As the incidence of cervical cancer continues to rise, the demand for Tivdak is expected to grow.

A significant development in the Tivdak market is its recent full approval by the FDA for the treatment of recurrent or metastatic cervical cancer. Regulatory approvals allow drugs to be marketed and used for medical purposes after proving their safety, efficacy, and quality. In April 2024, Pfizer, in collaboration with Genmab, received full FDA approval for Tivdak (tisotumab vedotin-tftv) for patients who have advanced after chemotherapy. This approval is noteworthy because Tivdak is the first antibody-drug conjugate to demonstrate improved overall survival in this patient population, with a median survival of 11.5 months compared to 9.5 months for chemotherapy. The approval followed positive Phase 3 trial results and highlighted Tivdak's manageable safety profile, including common side effects such as decreased hemoglobin levels and peripheral neuropathy.

In December 2023, Pfizer further strengthened its oncology portfolio by acquiring Seagen Inc., a biotechnology company that offers Tivdak. This acquisition aims to enhance Pfizer's pipeline, which now includes 60 oncology programs, positioning the company for significant growth in cancer treatments by 2030. Seagen’s expertise in antibody-drug conjugate technology will further drive Pfizer’s leadership in the oncology market.

Major players in the tivdak market are Genmab A/S, and Pfizer Inc.

North America was the largest region in the tivdak market in 2024. The regions covered in tivdak report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tivdak market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tivdak (tisotumab vedotin-tftv) is a prescription medication used to treat adults with recurrent or metastatic cervical cancer. It is specifically indicated for patients whose cancer has progressed during or after chemotherapy.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main clinical indications for Tivdak include recurrent or metastatic cervical cancer, second-line therapy for cervical cancer, and exploratory off-label uses. Recurrent or metastatic cervical cancer refers to cancer that has either returned (recurrent) or spread to other parts of the body (metastatic) after initial treatment. Tivdak can be administered both orally and parenterally through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies. It is used by end users such as hospitals, home care settings, and specialty clinics.

The tivdak market consists of sales of tivdak vials, sterile syringes and needles, IV infusion bags, infusion sets, and sterile water for injection. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.